HomeCompareIPCIF vs KO

IPCIF vs KO: Dividend Comparison 2026

IPCIF yields 1333.33% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPCIF wins by $241528700.57M in total portfolio value
10 years
IPCIF
IPCIF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full IPCIF calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — IPCIF vs KO

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPCIFKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPCIF + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPCIF pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, IPCIF beats the other by $178,904,481,057,887.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + KO for your $10,000?

IPCIF: 50%KO: 50%
100% KO50/50100% IPCIF
Portfolio after 10yr
$120764350.32M
Annual income
$105,237,930,038,355.17/yr
Blended yield
87.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

IPCIF
No analyst data
Altman Z
-111.3
Piotroski
4/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys
0
KO buys
0
No recent congressional trades found for IPCIF or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPCIFKO
Forward yield1333.33%2.70%
Annual dividend / share$2.00$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%24.3%
Portfolio after 10y$241528700.61M$34.1K
Annual income after 10y$210,475,860,072,406.56$4,303.79
Total dividends collected$239239876.27M$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IPCIF vs KO ($10,000, DRIP)

YearIPCIF PortfolioIPCIF Income/yrKO PortfolioKO Income/yrGap
1← crossover$144,033$133,333.33$10,846$335.73+$133.2KIPCIF
2$1,948,924$1,794,807.89$11,829$430.64+$1.94MIPCIF
3$24,782,219$22,696,870.86$12,988$555.50+$24.77MIPCIF
4$296,245,945$269,728,970.81$14,372$721.34+$296.23MIPCIF
5$3,330,378,004$3,013,394,842.54$16,049$944.01+$3330.36MIPCIF
6$35,223,684,321$31,660,179,856.69$18,114$1,246.74+$35223.67MIPCIF
7$350,636,384,108$312,947,041,885.16$20,702$1,664.24+$350636.36MIPCIF
8$3,286,630,500,315$2,911,449,569,318.85$24,008$2,249.48+$3286630.48MIPCIF
9$29,021,346,295,663$25,504,651,660,325.88$28,317$3,085.19+$29021346.27MIPCIF
10$241,528,700,608,766$210,475,860,072,406.56$34,065$4,303.79+$241528700.57MIPCIF

IPCIF vs KO: Complete Analysis 2026

IPCIFStock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this IPCIF vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHDIPCIF vs JEPIIPCIF vs OIPCIF vs MAINIPCIF vs PEPIPCIF vs PGIPCIF vs JNJIPCIF vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.